Generic Name

Acrisorcin

---

Classification

FDA Approved Indications

• Treatment of fungal infections of the skin and nails

Mechanism of Action

Inhibits squalene epoxidase, an enzyme involved in the ergosterol synthesis pathway in fungi, leading to increased cell membrane permeability and fungal cell death.

Dosage and Administration

Adult: Apply a thin layer to affected area once or twice daily, as directed by a healthcare professional.

Pediatric: Use as directed by a healthcare professional; safety and effectiveness in pediatric patients have not been fully established.

Geriatric: Use with caution; consider potential for impaired skin integrity and absorption.

Renal Impairment: No specific dose adjustment needed, but monitor for local irritation.

Hepatic Impairment: No specific data; use with caution.

Pharmacokinetics

Absorption: Minimal systemic absorption when applied topically.

Distribution: Primarily localized in skin and nail tissues.

Metabolism: Metabolized locally at the application site; systemic metabolism data are limited.

Excretion: Excreted via skin and nail keratin.

Half Life: Not applicable for topical use; systemic half-life not established.

Contraindications

• Hypersensitivity to terbinafine or any component of the formulation.

Precautions

• Avoid contact with eyes or mucous membranes.
• Discontinue if hypersensitivity reactions occur.
• Use cautiously in patients with extensive or severe fungal infections.

Adverse Reactions - Common

• Local irritation (e.g., redness, itching, burning) (Common)
• Skin dryness or peeling (Common)

Adverse Reactions - Serious

• Severe allergic reaction (rare) (Rare)
• Liver enzyme abnormalities (rare, typically with systemic terbinafine, but monitor if systemic absorption occurs) (Rare)

Drug-Drug Interactions

• None well-established for topical use.

Drug-Food Interactions

• None

Drug-Herb Interactions

• None known

Nursing Implications

Patient/Family Teaching

• Apply as directed, do not use on open wounds or mucous membranes.
• Report any signs of allergic reactions or irritation.
• Complete the full course of therapy, even if symptoms improve.

Special Considerations

Black Box Warnings:

• None currently issued.

Genetic Factors: N/A

Lab Test Interference: N/A

Overdose Management

Signs/Symptoms: Local irritation or allergic reaction; systemic toxicity is unlikely with topical use.

Treatment: Remove the medication, apply soothing topical agents, and seek medical advice if needed.

Storage and Handling

Storage: Store at room temperature, away from excess heat and moisture.

Stability: Stable when stored properly, check expiration date before use.